November 20, 2018
SkinBioTherapeutics kicks off final phase of SkinBiotix study
SkinBioTherapeutics has begun the final phases of its human study of SkinBiotix, to ensure that the original technology retains the same…
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
November 19, 2018
Immunocore, Genentech in skin cancer T-cell redirection therapy co-development
A T Cell Receptor (TCR) biotechnology specialist Immunocore Limited, has entered into a new partnership with Genentech, a member of…
November 14, 2018
Basilea presents anticancer drug candidate on a symposium in Ireland
Basilea Pharmaceutica will presenting its new preclinical data on its clinical stage anticancer drug candidate BAL101553 at the 30 EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland.
November 8, 2018
FDA prioritizes Dupinex for review
The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the @Regeneron Pharmaceuticals and Sanofi made supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable.
November 2, 2018
Illumina buys Pacific Biosciences for $1.2 Billion
Illumina will acquire Pacific Biosciences for $1.2 billion, it was revealed on Friday, after the agreement had been approved by the board of directors of Illumina and Pacific Biosciences.
$ILMN $PACB
November 1, 2018
Denali, Sanofi together developing RIPK1 inhibitors for treating neurological and inflammatory diseases
Denali Therapeutics will work with Sanofi on its multiple RIPK1 inhibitor molecules that could treat a range of neurological and systemic inflammatory diseases.
November 1, 2018
Quicker pathway to a pivotal trial for larger patient population than planned for Actinium’s CD33
@ActiniumPharma moves to next stage of development for its CD33 ARC (Antibody Radiation Conjugate) Ac-225-Lintuzumab program are pivotal trial pathway for its Actimab-MDS program for Myelodysplastic Syndromes (MDS), and also in two combination trials with Venetoclax for AML.
$ATNM
October 31, 2018
Plasticell bags €3.7 million EU funds for advancing neurodegenerative disease research
Advanced Stem Cell Training Network (ASCTN), a European research consortium , has successfully bid for over €3,700,000 in funding from the European Union to create and exploit advanced cellular models of neurological disorders – notably Parkinson´s, Huntington´s and Demyelination disease – which are caused by acute or progressive loss of cells in the brain, said Plasticell Ltd, a developer of stem cell technologies and regenerative medicines, in which the company is a partner organisation
October 30, 2018
Price Increase on Calcium Carbonate products in US and Canada
Omya, a producer of industrial minerals informed Monday about a price increase of 7 – 9% for its Calcium Carbonate products in the US and Canada, from the start of the next year.
October 29, 2018
N4 Pharma’s Nuvec can deliver system for vaccines and cancer treatments
@n4pharma with MedImmune UK, has been studying the level of immune response Nuvec can deliver when combined with a target antigen in a study using messenger RNA (mRNA) and plasmid DNA (pDNA) encoded with the standard test antigen Ovalbumin (OVA).